Recombinant Factor VIII (Kogenate FS, BAY14-2222)

Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A

Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Latin America

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment

Kogenate FS Regulatory Post-Marketing Surveillance

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS

Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222

EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE® FS in Taiwan

Prophylaxis Versus On-demand Therapy Through Economic Report